Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer

DENEB: Development of a new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy

Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stage I to III Colorectal Cancer

A multicenter, prospective observational study to evaluate the impact of circulating tumor DNA guided therapy on patients with colorectal ca

Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy effi

Early detection of circulating tumor DNA post-operatively enables discovery of resectable metastatic disease in a patient with colon cancer

Post-operative ctDNA monitoring in stage I colon cancer: A case report

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

Powles T, Assaf ZA, Davarpanah N, et al. Nature.

Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder

Szabados B, Kockx M, Assaf ZA, et al. European Urology.

Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survival.

Treatment response monitoring using a tumor-informed circulating tumor DNA test in an advanced triple negative breast cancer patient: A case

Reply to Di Cosimo et al.: Advancing circulating tumor DNA for recurrent breast cancer

Advancing Circulating Tumor DNA for Recurrent Breast Cancer

A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination gen

Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse

CIRCULATE-JP GALAXY Nature Medicine Summary

Early reduction in ctDNA is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma patients

10-Year Anora Clinical Study

Signatera in Advanced CRC